HC Wainwright & Co. initiated coverage of NervGen Pharma (NasdaqCM:NGEN) with a Buy rating on April 27, 2026. The analyst price forecast implies 47.65% upside, a constructive signal for the small-cap biotech name. The article is limited to analyst coverage and does not include any operational updates or financial results.
HC Wainwright & Co. initiated coverage of NervGen Pharma (NasdaqCM:NGEN) with a Buy rating on April 27, 2026. The analyst price forecast implies 47.65% upside, a constructive signal for the small-cap biotech name. The article is limited to analyst coverage and does not include any operational updates or financial results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
